Journal of Antimicrobial Chemotherapy
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Outcomes of early switching from intravenous to oral antibiotics on medical wards
2009
-
Activity of moxifloxacin against Streptococcus pneumoniae using a murine lung-infection model
2001
-
Efficacy of once-daily gemifloxacin for 5 days compared with twice-daily clarithromycin for 7 days in the treatment of AECB
2001
-
Efficacy of oral gemifloxacin (7-14 days) compared with intravenous ceftriaxone followed by oral cefuroxime (each given for 1-7 days, +/- a macrolide) in the treatment of CAP
2001
-
Gemifloxacin long-term outcomes in bronchitis exacerbations (GLOBE) study - An assessment of health outcome benefits in aecb patients following 5 days' gemifloxacin (GEMI) therapy
2001
-
Transfer of fluoroquinolone (FQ) resistance through recombination
2001
-
Triazole antifungal drug interactions—practical considerations for excellent prescribing.
79:1203-1217.
2024
-
Thiocillin and micrococcin exploit the ferrioxamine receptor of Pseudomonas aeruginosa for uptake.
76:2029-2039.
2021
-
Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines.
76:729-737.
2021
-
Study reporting quality among interventions to reduce antibiotic use is a barrier to evidence-informed policymaking on antimicrobial resistance: systematic review.
75:1091-1098.
2020
-
Meropenem potentiation of aminoglycoside activity against Pseudomonas aeruginosa: involvement of the MexXY-OprM multidrug efflux system.
73:1247-1255.
2018
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
72:3406-3413.
2017
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
72:3501-3501.
2017
-
Pharmacodynamics of dose-escalated ‘front-loading’ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.
72:2297-2303.
2017
-
Prevalence and correlates of MRSA and MSSA nasal carriage at a Ugandan regional referral hospital.
72:dkw472-dkw472.
2017
-
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
71:1747-1747.
2016
-
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
71:718-726.
2016
-
Multifaceted intervention to optimize antibiotic use for intra-abdominal infections.
70:1226-1229.
2015
-
An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria.
69:1844-1855.
2014
-
Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada.
69:637-642.
2014
-
Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009.
68:1505-1509.
2013
-
In vitro evaluation of the potential for resistance development to ceragenin CSA-13.
67:2665-2672.
2012
-
Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09.
67:2755-2765.
2012
-
Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).
67:1359-1367.
2012
-
Comment on: Ethical dilemmas in antibiotic treatment.
67:1302-1303.
2012
-
Characterization of extended-spectrum -lactamase-producing isolates of Haemophilus parainfluenzae.
61:509-514.
2008
-
Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review.
60:921-928.
2007
-
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study authors' response.
60:903-903.
2007
-
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
60:112-120.
2007
-
Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species.
57:899-907.
2006
-
High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. J Antimicrob Chemother 2005; 55: 748–57].
56:433-434.
2005
-
Meta-analysis of bacterial resistance to macrolides—providing generalizable results: authors' response.
56:434-435.
2005
-
Meta-analysis of bacterial resistance to macrolides.
55:748-757.
2005
-
Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon.
54:680-683.
2004
-
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
48:67-74.
2001
-
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients.
46:1001-1008.
2000
-
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study..
46:1001-1008.
2000
-
Progress in the management of urinary tract infections: discussion.
46:63-65.
2000
-
Gemifloxacin: survival of the fittest.
46:33-37.
2000
-
Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy.
44:811-817.
1999
-
Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
44:515-523.
1999
-
Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin.
43:549-554.
1999
-
Increase in the incidence of multidrug-resistant salmonellae in Ethiopia.
41:421-423.
1998
-
Antimicrobial activity of ceftriaxone versus cefotaxime: negative effect of serum albumin binding of ceftriaxone.
33:1239-1243.
1994
-
Synergistic killing of Gram-negative bacilli by cefotaxime, its desacetyl metabolite and human polymorphonuclear neutrophils.
27:817-828.
1991
-
The in-vitro activity of temafloxacin, against Gram-positive bacteria.
28:15-24.
1991
-
Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects.
24:573-580.
1989
-
A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia.
20:95-107.
1987
-
A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia.
12:9-20.
1983
-
A preliminary report on the use of ceftizoxime vs. clindamycin/tobramycin for the therapy of intra-abdominal and pelvic infections.
10:191-192.
1982
-
Biological effects of nitrofurans.
3:517-520.
1977
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)